Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 8/2018

01-08-2018 | Original Paper

Post-exposure Prophylaxis Awareness, Knowledge, Access and Use Among Three Populations in New York City, 2016–17

Authors: Beryl A. Koblin, DaShawn Usher, Vijay Nandi, Hong-Van Tieu, Eddie Bravo, Debbie Lucy, London Miles, Geneva Ortiz, Marcia J. Kindlon, Donna M. Parisi, Victoria Frye

Published in: AIDS and Behavior | Issue 8/2018

Login to get access

Abstract

Post-exposure prophylaxis (PEP) is a cost-effective, but underused HIV prevention strategy. PEP awareness, knowledge, access, and usage was assessed among young men of color who have sex with men (YMSMOC; n = 177), transgender women (TW; n = 182), and cisgender women of color (CWOC; n = 170) in New York City. 59% were aware of PEP: 80% among YMSMOC, 63% among TW and 34% among CWOC (p < 0.001). 13% had ever used PEP. PEP awareness was higher among YMSMOC with a recent HIV test and lower among those with ≥ 4 partners. PEP awareness was lower among TW who anticipated stigma and reported barriers to taking PEP, and higher among TW who exchanged sex for resources. Among CWOC, more barriers to taking PEP reduced the odds of PEP awareness. PEP education and outreach needs to be deliberate about population-specific campaigns, with a need to focus on reducing PEP stigma and other barriers which impede PEP access.
Literature
1.
2.
3.
Habarta N, Wang G, Mulatu MS, Larish N. HIV testing by transgender status at centers for disease control and prevention-funded sites in the United States, Puerto Rico, and US Virgin Islands, 2009–2011. American Journal of Public Health. 2015;105(9):1917–25.CrossRefPubMedPubMedCentral
4.
Herbst JH, Jacobs ED, et al. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behaviour. 2008;12(1):1–17.CrossRef
5.
Rapues J, Wilson EC, Packer T, Colfax GN, Raymond HF. Correlates of HIV infection among transfemales, San Francisco, 2010: results from a respondent-driven sampling study. American Journal of Public Health. 2013;103(8):1485–92.CrossRefPubMedPubMedCentral
6.
7.
8.
Fitzpatrick LJ, Egan DJ, et al. Nonoccupational post-exposure prophylaxis for HIV in New York State Emergency Departments. Journal of the International Association of Providers of AIDS Care. 2014;13(6):539–46.CrossRefPubMed
9.
Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human Services. MMWR Recommendations and Reports. 2005;54:1–20.PubMed
10.
Krakower DS, Jain S, Mayer KH. Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis. Current HIV/AIDS Reports. 2015;12(1):127–38.CrossRefPubMedPubMedCentral
11.
Dolezal C, Frasca T, Giguere R, et al. Awareness of post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) is low but interest is high among men engaging in condomless anal sex with men in Boston, Pittsburgh, and San Juan. AIDS Education and Prevention. 2015;27(4):289–97.CrossRefPubMedPubMedCentral
12.
Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clinical Infectious Diseases. 2004;39(3):395–401.CrossRefPubMed
13.
Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. Aids. 2004;18(15):2065–73.CrossRefPubMed
14.
Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Archives of Internal Medicine. 2004;164(1):46–54.CrossRefPubMed
15.
Jain S, Mayer KH. Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review. Aids. 2014;28(11):1545–54.CrossRefPubMedPubMedCentral
16.
Jain S, Oldenburg CE, Mimiaga MJ, Mayer KH. Longitudinal trends in HIV nonoccupational postexposure prophylaxis use at a Boston community health center between 1997 and 2013. Journal of Acquired Immune Deficiency Syndromes. 2015;68(1):97–101.CrossRefPubMed
17.
Siemieniuk RA, Sivachandran N, Murphy P, et al. Transitioning to HIV pre-exposure prophylaxis (PrEP) from non-occupational post-exposure prophylaxis (nPEP) in a comprehensive hiv prevention Clinic: a prospective cohort study. AIDS Patient Care and STDs. 2015;29(8):431–6.CrossRefPubMed
18.
Doblecki-Lewis S, Lester L, Schwartz B, Collins C, Johnson R, Kobetz E. HIV risk and awareness and interest in pre-exposure and post-exposure prophylaxis among sheltered women in Miami. International Journal of STD and AIDS. 2016;27(10):873–81.CrossRefPubMed
19.
Palich R, Martin-Blondel G, Cuzin L, et al. Experiences of HIV postexposure prophylaxis (PEP) among highly exposed men who have sex with men (MSM). Sexually Transmitted Infections. 2017;93:493–8.CrossRefPubMed
20.
Liu AY, Kittredge PV, Vittinghoff E, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. Journal of Acquired Immune Deficiency Syndromes. 2008;47(2):241–7.PubMed
21.
Millett GA, Peterson JL, Flores SA, et al. Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: a meta-analysis. Lancet. 2012;380(9839):341–8.CrossRefPubMed
22.
Wolitski RJ, Fenton KA. Sexual health, HIV, and sexually transmitted infections among gay, bisexual, and other men who have sex with men in the United States. AIDS Behaviour. 2011;15(Suppl 1):S9–17.CrossRef
23.
Walters SM, Rivera AV, Starbuck L, et al. Differences in awareness of pre-exposure prophylaxis and post-exposure prophylaxis among groups at-risk for HIV in New York State: New York City and Long Island, NY, 2011–2013. Journal of Acquired Immune Deficiency Syndromes. 2017;75(Suppl 3):S383–91.CrossRefPubMed
24.
Farhat D, Greene E, Paige MQ, Koblin BA, Frye V. Knowledge, stereotyped beliefs and attitudes around HIV chemoprophylaxis in two high HIV prevalence neighborhoods in New York City. AIDS Behaviour. 2017;21(5):1247–55.CrossRef
25.
Peterman TA, Newman DR, Maddox L, Schmitt K, Shiver S. Risk for HIV following a diagnosis of syphilis, gonorrhoea or chlamydia: 328,456 women in Florida, 2000-2011. International Journal of STD and AIDS. 2015;26(2):113–9.CrossRefPubMed
26.
Khan MR, Epperson MW, Mateu-Gelabert P, Bolyard M, Sandoval M, Friendman SR. Incarceration, sex with an STI- or HIV-infected partner, and infection with an STI or HIV in Bushwick, Brooklyn, NY: a social network perspective. American Journal of Public Health. 2011;101(6):1110–7.CrossRefPubMedPubMedCentral
27.
Haire BG. Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence—a narrative review. HIV AIDS (Auckland). 2015;7:241–9.PubMedCentral
28.
Smith DK, Maier E, Betts J, Gray S, Kolodziejski B, Hoover KW. What community-based HIV prevention organizations say about their role in biomedical HIV prevention. AIDS Education and Prevention. 2016;28(5):426–39.CrossRefPubMed
29.
30.
LaCroix JM, Snyder LB, Huedo-Medina TB, Johnson BT. Effectiveness of mass media interventions for HIV prevention, 1986–2013: a meta-analysis. JAIDS. 2014;66:S329–40.PubMed
31.
32.
Young B, Lewis S, Katikiereddi SV, et al. Effectiveness of mass media campaigns to reduce alcohol consumption and harm: a systematic review. Alcohol Alcohol. 2018;53(3):302–16.CrossRefPubMedPubMedCentral
33.
34.
Mayer KH, Jones D, Oldenburg C, et al. Optimal HIV postexposure prophylaxis regimen completion with single tablet daily elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine compared with more frequent dosing regimens. Journal of Acquired Immune Deficiency Syndromes. 2017;75(5):535–9.CrossRefPubMed
35.
Calabrese SK, Underhill K. How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: a call to destigmatize “truvada whores”. American Journal of Public Health. 2015;105(10):1960–4.CrossRefPubMedPubMedCentral
36.
Prati G, Zani B, Pietrantoni L, et al. PEP and TasP awareness among Italian MSM, PLWHA, and high-risk heterosexuals and demographic, behavioral, and social correlates. PLoS ONE. 2016;11(6):e0157339.CrossRefPubMedPubMedCentral
37.
Oldenburg CE, Perez-Brumer AG, Hatzenbuehler ML, et al. State-level structural sexual stigma and HIV prevention in a national online sample of HIV-uninfected MSM in the United States. Aids. 2015;29(7):837–45.CrossRefPubMedPubMedCentral
Metadata
Title
Post-exposure Prophylaxis Awareness, Knowledge, Access and Use Among Three Populations in New York City, 2016–17
Authors
Beryl A. Koblin
DaShawn Usher
Vijay Nandi
Hong-Van Tieu
Eddie Bravo
Debbie Lucy
London Miles
Geneva Ortiz
Marcia J. Kindlon
Donna M. Parisi
Victoria Frye
Publication date
01-08-2018
Publisher
Springer US
Published in
AIDS and Behavior / Issue 8/2018
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-018-2175-5

Other articles of this Issue 8/2018

AIDS and Behavior 8/2018 Go to the issue

Original Paper

Prevalence of and Factors Associated with the Use of HIV Serosorting and Other Biomedical Prevention Strategies Among Men Who Have Sex with Men in a US Nationwide Survey

Original Paper

Past Care Predicts Future Care in Out-of-Care People Living with HIV: Results of a Clinic-Based Retention-in-Care Intervention in North Carolina

Original Paper

A Conceptual Model of Dyadic Coordination in HIV Care Engagement Among Couples of Black Men Who Have Sex with Men: A Qualitative Dyadic Analysis

Original Paper

Sex Trade and Health Care Utilization Among People Living with HIV/AIDS

Original Paper

HIV-Related Healthcare Needs and Access Barriers for Brazilian Transgender and Gender Diverse People

Original Paper

Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits